Navigation Links
Regulus Presents Positive Preclinical Data Demonstrating that microRNA-21 Plays an Important Role in Alport Syndrome
Date:11/8/2013

LA JOLLA, Calif., Nov. 8, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that positive new preclinical data demonstrating that microRNA-21 (miR-21) plays an important role in Alport Syndrome will be presented at the American Society of Nephrology's Kidney Week 2013 meeting being held November 5-10 in Atlanta, GA.

In a poster presentation titled "Identification of the Pathologic Role of miR-21 in Alport's Kidney Disease" on Friday, November 8, 2013 from 10:00 a.m. EST to 12:00 p.m. EST, Regulus and Genzyme, a Sanofi company, presented new preclinical data demonstrating that miR-21 plays an important role in the disease progression of Alport Syndrome in collagen 4A3 deficient mice.  The study assessed urine albumin, kidney function, pathology and gene expression in the mice at 4, 6, 9, 12 and 15 weeks of age.  Efficacy of an anti-miR-21 candidate was assessed in mice starting at 5 weeks of age.  Urine albumin, renal function, kidney pathology and lifespan were used as efficacy endpoints.  Treatment with an anti-miR-21 candidate significantly improved renal function, significantly reversed regulated genes and pathways associated with renal pathology, and increased the lifespan of the mice by 20 percent. The poster can be accessed on Regulus' website, http://www.regulusrx.com.

"We are extremely pleased with the results from this study and believe these positive data validate that treatment with an anti-miR-21 candidate may be an important new therapy for patients with Alport Syndrome," said Neil W. Gibson, Ph.D., Chief Scientific Officer at Regulus. "These data bring us one step clo
'/>"/>

SOURCE Regulus Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Regulus Announces Timing for Third Quarter 2013 Financial Results Webcast and Conference Call
2. Regulus Announces Significant Progress in Strategic Alliance with AstraZeneca and Selection of a New Pre-Clinically Validated microRNA Oncology Target
3. Regulus Reports Second Quarter 2013 Financial Results and Recent Highlights
4. Regulus Announces Timing for Second Quarter 2013 Financial Results Webcast and Conference Call
5. Regulus Names Stelios Papadopoulos, Ph.D. as Chairman of its Board of Directors
6. Regulus to Present at Deutsche Bank 38th Annual Healthcare Conference
7. Regulus Provides Update on Road to the Clinic Strategy and Reports First Quarter 2013 Financial Results and Recent Highlights
8. Regulus Announces Timing for First Quarter 2013 Financial Results Webcast and Conference Call
9. Regulus Appoints William H. Rastetter, Ph.D. to its Board of Directors
10. Regulus to Present at Future Leaders in the Biotech Industry Conference
11. Regulus to Present at Cowen and Company 33rd Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... Burzynski Research Institute, Inc. (BRI) announced today that the ... company permission to conduct an open-label study of Antineoplastons ... age with a diffuse intrinsic brainstem glioma (DIPG). Study ... groups based on their age and whether or not ... study endpoint is a decrease in the size of ...
(Date:10/22/2014)...  Rescheduling of hydrocodone combination products (HCPs) will ... according to a new primary market research study ... research and consultation exclusively in the area of ... In August, the DEA ... from Schedule III to Schedule II status. This ...
(Date:10/22/2014)... BASKING RIDGE, N.J. , Oct. 22, 2014 ... (RMANJ), a world-renowned leader in the field ... more rapid approach to embryonic screening. The research ... American Society for Reproductive Medicine (ASRM) meeting in ... chromosome screening (CCS) and single gene defect (SGD) ...
Breaking Medicine Technology:Burzynski Research Institute, Inc. Announces FDA Permission to Launch a New Clinical Trial in Diffuse Intrinsic Brainstem Glioma 2Hydrocodone: Rescheduled, Repositioned & Reinvented 2Hydrocodone: Rescheduled, Repositioned & Reinvented 3New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 3
... 26, 2012  Richard Wolf Medical Instruments Corporation celebrates ... minimally invasive solutions that spare patients the costs ... (Logo:  http://photos.prnewswire.com/prnh/20120426/CG95191LOGO ) ... allowing doctors to visualize and access elusive sites ...
... April 26, 2012 - The Consumer Healthcare Products ... for signing into law House Bill 363, legislation ... implementing a drug offender registry, stricter penalties for ... stop-sale technology.  HB 363 and its companion legislation ...
Cached Medicine Technology:Richard Wolf Medical Instruments Corporation: 40 Years of Innovation 2
(Date:10/25/2014)... The Wehrman Collaborative, LLC (WeCo) ... disabled users by disabled users, has granted use ... Educational Resources of Burnsville, Minnesota, for their ... the Minnesota Alliance for Patient Safety of Minneapolis, ... website. Both organizations have met WeCo’s Standards ...
(Date:10/25/2014)... Raleigh, NC (PRWEB) October 25, 2014 ... patient who continued to receive pemetrexed (Alimta), after his ... to read the full story , just posted on ... study from Uji Tokushukai Medical Center in Japan suggests ... for mesothelioma patients who cannot tolerate higher ...
(Date:10/25/2014)... FRIDAY, Oct. 24, 2014 (HealthDay News) -- Researchers ... say their findings are cause for concern. ... that are raised for human consumption contribute to ... health, according to background information from the study. ... germs sicken about 2 million people and kill ...
(Date:10/22/2014)... 2014 At a time when the ... and athletes at all levels, the UPMC Sports ... current discussion where two powerful messages are lost: Concussions ... result in full recoveries every day. , In striving ... fact and research, UPMC and the Concussion Program are ...
(Date:10/22/2014)... October 22, 2014 For Dr. Iris Hunter, ... money; it’s an extension of her life’s mission. Her extensive ... as the owner of FirstLight HomeCare, make it clear that ... to me that my work makes a difference in the ... entrepreneurial spirit, so after much research, I felt ready to ...
Breaking Medicine News(10 mins):Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 2Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 3Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Researchers Say Antibiotics in Fish a Health Concern 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 3Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 4Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2
... Medical,Inc. (Nasdaq: NXTM ), a leading manufacturer of ... a $50.0 million credit,and security agreement from a group ... Merrill Lynch Business Services Inc., for a term of,42 ... million term loan and a $20.0,million revolving credit facility. ...
... Research Hospital have discovered a new signaling molecule that ... body. The finding could lead to the development of ... such as Type 1 diabetes; and for inflammatory diseases, ... , The St. Jude team discovered that specialized immune ...
... Conn., Nov. 21 Therap Services will host ... 5-7, 2007 in,Southbury, Connecticut. The 2nd Direct Support ... Support Professionals who are daily,users of Therap as ... Therap,s users and its developers and support staff., ...
... survey found , WEDNESDAY, Nov. 21 (HealthDay News) -- Older ... stress, a new study shows. , A team of University ... 53 to 85 who worked at least 20 hours per ... male, 87 percent were white, about 8 percent were black, ...
... Nov. 21 Susan G. Komen for the ... breast cancer research and,community-based outreach programs, is accepting ... who lost a,parent to breast cancer., (Logo: ... Award helps students cover the costs of,tuition, books, ...
... Region activates when a friend,s voice calls, scientists say , ... they,ve spotted a brain region that selectively emphasizes certain sounds, ... person,s name. , Researchers from the University of Washington, Seattle, ... the experimental method they used to detect brain activity associated ...
Cached Medicine News:Health News:NxStage Medical Establishes $50 Million Credit Facility with a Group of Lenders Led by Merrill Lynch Capital 2Health News:NxStage Medical Establishes $50 Million Credit Facility with a Group of Lenders Led by Merrill Lynch Capital 3Health News:St. Jude finds molecule that could improve cancer vaccines and therapy for other diseases 2Health News:St. Jude finds molecule that could improve cancer vaccines and therapy for other diseases 3Health News:Therap Services to Host 2nd Conference for Direct Support Professionals 2Health News:Jobs Don't Stress Most Older Workers 2Health News:Susan G. Komen for the Cure Provides Scholarships for Students Who Lost a Parent to Breast Cancer 2
... 8F Percutaneous Vascular Surgical (PVS) System consists of ... Perclose Knot Pusher. The Prostar XL 8F PVS ... two pairs of sutured needles as well as ... precisely control the needles during deployment. the Perclose ...
... The new solid-state IRIS Medical IQ ... the treatment of retinal disorders and ... represents its latest technological innovation and ... Minimum Intensity Photocoagulation (MIP) procedures in ...
... The AIA-360 is a sophisticated Aumated Immunoassay Analyzer ... analyzer has a footprint of 16 X 16 ... Its compact design is ideal for physician ... testing, such as cardiac panels, as well as ...
... Solitaire represents the latest in green laser ... for use in both the operating room ... preference testing and the most experienced ophthalmic ... is the premium 532nm photocoagulator - unique ...
Medicine Products: